Induction of tolerance to a recombinant human enzyme, acid alpha-glucosidase, in enzyme deficient knockout mice

Transgenic Research

Volumn 12, Issue 2, 2003, Pages 171-178

  Raben, Nina ^a   Nagaraju, Kanneboyina ^a   Lee, Alicia ^a   Lu, Nina ^a   Rivera, Yesenia ^a   Jatkar, Tejas ^a   Hopwood, John J ^b   Plotz, Paul H ^a  

^a NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES   (United States)

^b WOMEN S AND CHILDREN S HOSPITAL   (Australia)

Author keywords

Antibodies; Lysosomal disorder; Tetracycline inducible system; Tolerance; Transgenic knockouts

Indexed keywords

ALPHA-GLUCOSIDASES; ANIMALS; AUTOANTIBODIES; CHO CELLS; CRICETINAE; DISEASE MODELS, ANIMAL; GLYCOGEN STORAGE DISEASE TYPE II; HUMANS; LIVER; MICE; MICE, KNOCKOUT; MICE, TRANSGENIC; PHENOTYPE; RECOMBINANT PROTEINS;

ANIMALIA;

EID: 0038732760     PISSN: 09628819     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1022998010833     Document Type: Article

References (36)

1. Abramczuk JW, Kearns-Jonker M, Monell-Torrens E, Wohlenberg C and Notkins AL (1991) Transgenic mouse lines that are immunologically tolerant and nontolerant to herpes simplex virus glycoprotein D. J Virol 65: 6124-6128.
2. Adelstein S, Pritchard-Briscoe H, Anderson TA, Crosbie J et al. (1991) Induction of self-tolerance in T cells but not B cells of transgenic mice expressing little self antigen. Science 251: 1223-1225.
3. Amalfitano A, McVie-Wylie AJ, Hu H, Dawson TL, Raben N, Plotz P and Chen YT (1999) Systemic correction of the muscle disorder glycogen storage disease type II after hepatic targeting of a modified adenovirus vector encoding human acid alpha-glucosidase. Proc Natl Acad Sci USA 96: 8861-8866.
4. Amalfitano A, Bengur RP, Morse JM, Majure LE, Case DL et al. (2001) Recombinant human acid alpha-glucosidase enzyme therapy for infantile glycogen storage disease type II: results of a phase I/II clinical trial. Genet Med 3: 132-138.
5. Bijvoet AG, Van de Kamp EH, Kroos MA, Ding JH, Yang BZ et al. (1998a) Generalized glycogen storage and cardiomegaly in a knockout mouse model of Pompe disease. Hum Mol Genet 7: 53-62.
6. Bijvoet AG, Kroos MA, Pieper FR, Van der Vliet M et al. (1998b) Recombinant human acid alpha-glucosidase: high level production in mouse milk, biochemical characteristics, correction of enzyme deficiency in GSDII KO mice. Hum Mol Genet 7: 1815-1824.
7. Bijvoet AG, Van Hirtum H, Kroos MA, Van de Kamp EH et al. (1999) Human acid alpha-glucosidase from rabbit milk has therapeutic effect in mice with glycogen storage disease type II. Hum Mol Genet 8: 2145-2153.
8. Brooks DA (1999) Immune response to enzyme replacement therapy in lysosomal storage disorder patients and animal models. Mol Genet Metab 68: 268-275.
9. -] adenovirus-mediated transfer of human acid-alpha-glucosidase gene into glycogen storage disease type II knockout mice. Hum Gene Ther 12: 955-965.
10. Evans GL and Morgan RA (1998) Genetic induction of immune tolerance to human clotting factor VIII in a mouse model for hemophilia A. Proc Natl Acad Sci USA 95: 5734-5739.
11. Fraites TJ, Schleissing MR, Shanely RA, Walter GA, Cloutier DA, Zolotukhin I et al. (2002) Correction of the enzymatic and functional deficits in a model of Pompe disease using adeno-associated virus vectors. Mol Ther 5: 571-578.
12. Fox IJ, Chowdhury JR, Kaufman SS, Goertzen TC et al. (1998) Treatment of the Crigler-Najjar syndrome type I with hepatocyte transplantation. N Engl J Med 338: 1422-1426.
13. Heim DA, Hanazono Y, Giri N, Wu T et al. (2000) Introduction of a xenogenic gene via hematopoietic stem cells leads to specific tolerance in a rhesus monkey model. Mol Ther 1: 533-544.
14. Hirschhorn R and Reuser AJ (2000) Glycogen storage disease type II: acid alpha-glucosidase (acid maltase) deficiency. In: Scriver CR, Beaudet AL, Sly WS and Valle D (eds), The Metabolic and Molecular Basis of Inherited Disease. (pp. 3389-3420) McGraw-Hill, New York.
15. Kakkis ED, McEntee MF, Schmidtchen A, Neufeld EF, Ward DA et al. (1996) Long-term and high-dose trials of enzyme replacement therapy in the canine model of mucopolysaccharidosis I. Biochem Mol Med 58: 156-167.
16. Kikuchi T, Yang HW, Pennybacker M, Ichihara N et al. (1998) Clinical and metabolic correction of Pompe disease by enzyme therapy in acid maltase-deficient quail. J Clin Invest 101: 827-833.
17. Kruisbeck AM and Shevach E (1996) Proliferative assays for T-cell function. In: Coligan JE, Kruisbeek AM, Marguies DH, Shevach EM and Strober W (eds), Current Protocols in Immunology. (pp. 1-21) Wiley, New York.
18. Lee LA (2001) Advances in hepatocyte transplantation: a myth becomes reality. J Clin Invest 108: 367-369.
19. Martiniuk F, Chen A, Donnabella V, Arvanitopoulos E et al. (2000) Correction of glycogen storage disease type II by enzyme replacement with a recombinant human acid maltase produced by over-expression in a CHO-DHFR(neg) cell line. Biochem Biophys Res Commun 276: 917-923.
20. Martin-Touaux E, Puech JP, Chateau D, Emiliani C, Kremer EJ, Raben N et al. (2002) Muscle as a putative producer of acid alpha-glucosidase for glycogenosis type II gene therapy. Hum Mol Genet 11: 1637-1645.
21. Menoret S, Aubert D, Tesson L, Braudeau C, Pichard V, Ferry N et al. (2002) LacZ transgenic rats tolerant for β-galactosidase: recipients for gene transfer studies using lacZ as a reporter gene. Hum Gene Ther 13: 1383-1390.
22. Pauly DF, Fraites TJ, Toma C, Bayes HS, Huie ML et al. (2001) Intercellular transfer of the virally derived precursor form of acid alpha-glucosidase corrects the enzyme deficiency in inherited cardioskeletal myopathy Pompe disease. Hum Gene Ther 12: 527-538.
23. Qian J, Borovok M, Bi L, Kazazian Jr HH and Hoyer LW (1999) Inhibitor antibody development and T cell response to human factor VIII in murine hemophilia A. Thromb Haemost 81: 240-244.
24. Raben N, Nagaraju K, Lee E, Kessler P, Byrne B et al. (1998) Targeted disruption of the acid α-glucosidase gene in mice causes an illness with critical features of both infantile and adult human glycogen storage disease type II. J Biol Chem 273: 19086-19092.
25. Raben N, Nagaraju K, Lee E and Plotz P (2000a) Modulation of disease severity in mice with targeted disruption of the acid alpha-glucosidase gene. Neuromuscular Disord 10: 283-291.
26. Raben N, Lu N, Nagaraju K, Rivera Y, Lee A et al. (2001) Conditional tissue-specific expression of the acid alpha-glucosidase (GAA) gene in the GAA knockout mice: implications for therapy. Hum Mol Genet 10: 2039-2047.
27. Raben N, Plotz P and Byrne B (2002a) Acid alpha-glucosidase deficiency (glycogenosis type II, Pompe disease). Current Mol Med 2: 145-166.
28. Raben N, Jatkar T, Lee A, Lu N, Dwivedi S, Nagaraju K et al. (2002b) Glycogen stored in skeletal but not in cardiac muscle in acid α-glucosidase mutant (Pompe) mice is highly resistant to transgene-encoded human enzyme. Mol Ther 6: 601-608.
29. Reuser AJJ, Koster F, Hoogeveen A and Galjaard H (1978) Biochemical, immunological, and cell genetic studies in glycogenosis type II. Am J Hum Genet 30: 132-143.
30. Shull RM, Lu X, McEntee MF, Bright RM, Pepper KA, Kohn DB (1996) Myoblast gene therapy in canine mucopolysaccharidosis I: abrogation by an immune response to alpha-L-iduronidase. Hum Gene Ther 7: 1595-1603.
31. Sly WS, Vogler C, Grubb JH, Zhou M, Jiang J et al. (2001) Active site mutant transgene confers tolerance to human beta-glucuronidase without affecting the phenotype of MPS VII mice. Proc Natl Acad Sci USA 98: 2205-2210.
32. Taniguchi H, Toyoshima T, Fukao K and Nakauchi H (1996) Presence of hematopoietic stem cells in the adult liver. Nat Med 2: 198-203.
33. Umapathysivam K, Whittle AM, Ranieri E, Bindloss C et al. (2000) Determination of acid alpha-glucosidase protein: evaluation as a screening marker for Pompe disease and other lysosomal storage disorders. Clin Chem 46: 1318-1325.
34. Van den Driessche T, Vanslembrouck V, Goovaerts I, Zwinnen H et al. (1999) Long-term expression of human coagulation factor VIII and correction of hemophilia A after in vivo retroviral gene transfer in factor VIII-deficient mice. Proc Natl Acad Sci USA 96: 10379-10384.
35. Van den Hout H, Reuser AJ, Vulto AG, Loonen MC, Cromme-Dijkhuis A and Van der Ploeg AT (2000) Recombinant human alpha-glucosidase from rabbit milk in Pompe patients. Lancet 356: 397-398.
36. Van den Hout H, Reuser AJ, de Klerk JB, Arts WF, Smeitink JA and Van der Ploeg AT (2001) Enzyme therapy for Pompe disease with recombinant human alpha-glucosidase from rabbit milk. J Inherit Metab Dis 24: 266-274.